首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症

北美肺癌篩檢市場預測至 2030 年 - 區域分析 - 按癌症類型、技術、年齡層（50 歲及以上和 50 歲以下）和最終用戶（醫院、診斷中心等）

市場調查報告書

商品編碼

1402531

北美肺癌篩檢市場預測至 2030 年 - 區域分析 - 按癌症類型、技術、年齡層（50 歲及以上和 50 歲以下）和最終用戶（醫院、診斷中心等）

North America Lung Cancer Screening Market Forecast to 2030 - Regional Analysis - by Cancer Type, Technology, Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)

出版日期: 2023年11月07日 | 出版商:

The Insight Partners | 英文 100 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

北美肺癌篩檢市場預計將從2022年的9.6541億美元成長到2030年的18.1148億美元。預計2022年至2030年CAGR為8.2%。

不斷增加的政府支持推動了北美肺癌篩檢市場。

肺癌是全世界死亡的主要原因之一。肺癌篩檢是癌症預防方法的重要組成部分。早期診斷出肺癌患者的預後會更好，因此鼓勵肺癌高風險族群進行常規檢查，以檢測肺部癌性生長的形成。根據美國癌症協會估計，2023年美國肺癌新病例約238,340例；其中，女性 120,790 人，男性 117,550 人。因此，全球肺癌發生率的上升推動了肺癌篩檢計畫的啟動，這反過來又推動了市場的成長。

北美肺癌篩檢市場概況

北美肺癌篩檢市場分為美國、加拿大和墨西哥。該地區的成長歸因於多種因素，例如肺癌發病率的增加以及人們對吸煙副作用的認知。此外，政府對篩檢的支持不斷增加，導致市場進一步成長。

在北美，美國在北美肺癌篩檢市場中佔有重要佔有率。該國的市場成長主要是由肺癌發病率上升和政府措施推動的。肺癌是美國男性和女性第二常見的癌症。根據美國癌症協會的數據，截至 2023 年，美國約有 238,340 名成年人（117,550 名男性和 120,790 名女性）被診斷出患有肺癌，約 127,070 名成年人（67,160 名男性和 59,910 名女性）死亡。肺癌佔所有癌症死亡的五分之一，使其成為美國癌症死亡的主要原因。這些統計數據包括小細胞肺癌和非小細胞肺癌。 NSCLC 是最常見的肺癌類型，佔所有肺癌診斷的 81%。在美國，所有類型肺癌的 5 年相對存活率為 23%，對於非小細胞肺癌，男性和女性的 5 年相對存活率分別為 23% 和 33%。在美國，建議以一種稱為低劑量螺旋或螺旋電腦斷層掃描（CT 或 CAT）掃描的測試來篩檢肺癌。預防服務工作小組 (USPSTF) 建議，50-80 歲、有 20 包或以上吸菸史或在過去 15 年內戒菸的人每年應進行低劑量 CT 掃描篩檢肺癌。根據數位策略辦公室管理的白宮官方網站 Whitehouse.gov 於 2023 年 5 月發布的報告，社區癌症中心協會 (ACCC) 和阿斯特捷利康正在建立合作夥伴關係，以開發和實施透過「農村阿巴拉契亞肺癌篩檢計劃”，以人為本和永續的方法來增加美國農村地區的肺癌篩檢。阿巴拉契亞地區（包括整個西維吉尼亞州和其他 12 個州的部分地區）的癌症死亡率比美國其他地區高 10%。該計劃的目標是將肺癌的五年存活率提高一倍。此類措施正在促進美國北美肺癌篩檢市場的成長。

北美肺癌篩檢市場收入及 2030 年預測（百萬美元）

北美肺癌篩檢市場細分

北美肺癌篩檢市場按癌症類型、技術、年齡層、最終用戶和國家細分。

根據癌症類型，北美肺癌篩檢市場分為非小細胞肺癌（NSCLC）和小細胞肺癌。 2022 年，非小細胞肺癌 (NSCLC) 細分市場在北美肺癌篩檢市場中佔據更大佔有率。

根據技術，北美肺癌篩檢市場分為胸部X光檢查、低劑量電腦斷層掃描（LDCT）、液體切片等。 2022 年，低劑量電腦斷層掃描 (LDCT) 領域在北美肺癌篩檢市場中佔據最大佔有率。

根據年齡層，北美肺癌篩檢市場分為50歲及以上及50歲以下。2022年，50歲及以上細分市場在北美肺癌篩檢市場中佔據較大佔有率。

根據最終用戶，北美肺癌篩檢市場分為醫院、診斷中心等。 2022年，醫院部門在北美肺癌篩檢市場中佔據最大佔有率。

按國家/地區分類，北美肺癌篩檢市場分為美國、加拿大和墨西哥。 2022年，美國在北美肺癌篩檢市場佔據主導地位。

西門子股份公司、荷蘭皇家飛利浦公司、佳能公司、美敦力公司、GE HealthCare、Nuance Communications Inc、LungLife AI, Inc、Intelerad Medical Systems、bioAffinity Technologies, Inc 和 CSV Health 是北美肺癌篩檢領域的一些領先公司市場。

Lung cancer is among the main causes of mortality across the world. Lung cancer screening is a critical component of cancer prevention approaches. The prognosis for lung cancer patients is better when the disease is diagnosed early, so people at high risk of lung cancer are encouraged to undergo routine testing to detect the formation of cancerous growth in their lungs. According to estimates by the American Cancer Society for lung cancer in the US for 2023, about 238,340 new lung cancer cases were registered; of these, 120,790 in women and 117,550 in men were reported. Thus, the rising incidence of lung cancer worldwide is contributing to the initiation of lung cancer screening programs, which is, in turn, driving the market growth.

North America Lung Cancer Screening Market Overview

The North America, Lung Cancer Screening Market is segmented into the US, Canada, and Mexico. The regional growth is attributed to various factors, such as the increasing incidence of lung cancer and awareness of side effects of cigarette smoking among people. Also, rising government support for screening has led to the further growth of the market.

In North America, the US holds a significant share of the North America Lung Cancer Screening Market . The market growth in this country is primarily driven by the increasing incidence of lung cancer and government initiatives. Lung cancer is the second most common cancer in both men and women in the US. As per the American Cancer Society, Inc., as of 2023, approximately 238,340 adults (117,550 men and 120,790 women) in the US have been diagnosed with lung cancer, and ~127,070 (67,160 in men and 59,910 in women) have succumbed to death due to the disease. Lung Cancer accounts for 1 in 5 of all cancer death, making it a leading cause of cancer death in the US. These statistics include both small cell lung cancer and NSCLC. NSCLC is the most common type of lung cancer, accounting for 81% of all lung cancer diagnoses. For all types of lung cancer in the US, the 5-year relative survival rate is 23%, and for NSCLC, the 5-year relative survival rate for men and women is 23% and 33%, respectively. In the US, screening for lung cancer is recommended with a test called a low-dose helical or spiral computed tomography (CT or CAT) scan. Preventive Services Task Force (USPSTF) recommends that people aged 50-80, with a history of smoking 20 pack years or more, or who have quit within the past 15 years should go through screening for lung cancer with low-dose CT scans each year. As per the report published in the whitehouse.gov, the official website of the White House, managed by the Office of Digital Strategy in May 2023, the Association of Community Cancer Centers (ACCC) and AstraZeneca are entering into a partnership to develop and implement person-centered and sustainable approaches to increase lung cancer screening in rural America through the "Rural Appalachian Lung Cancer Screening Initiative." The cancer mortality rate in the Appalachian region, including all of West Virginia and parts of 12 other states, is 10% higher than that in the rest of the US. The aim of this initiative is to double the five-year survival rate for lung cancer. Such initiatives are contributing to the North America Lung Cancer Screening Market growth in the US.

North America Lung Cancer Screening Market Revenue and Forecast to 2030 (US$ Million)

North America Lung Cancer Screening Market Segmentation

The North America lung cancer screening market is segmented into cancer type, technology, age group, end user, and country.

Based on cancer type, the North America lung cancer screening market is segmented into non-small cell lung cancer (NSCLC), and small cell lung cancer. The non-small cell lung cancer (NSCLC) segment held a larger share of the North America lung cancer screening market in 2022.

Based on technology, the North America lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. Low dose computed tomography (LDCT) segment held the largest share of the North America lung cancer screening market in 2022.

Based on age group, the North America lung cancer screening market is segmented into 50 and older, and below 50. 50 and older segment held the larger share of the North America lung cancer screening market in 2022.

Based on end user, the North America lung cancer screening market is segmented into hospital, diagnostic centre, and others. Hospital segment held the largest share of the North America lung cancer screening market in 2022.

Based on country, the North America Lung Cancer Screening Market is segmented into the US, Canada, and Mexico. The US dominated the North America lung cancer screening market in 2022.

Siemens AG, Koninklijke Philips NV, Canon Inc, Medtronic, GE HealthCare, Nuance Communications Inc, LungLife AI, Inc, Intelerad Medical Systems, bioAffinity Technologies, Inc, and CSV Health are some of the leading companies operating in the North America lung cancer screening market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America Lung Cancer Screening Market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in North America Lung Cancer Screening Market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth North America Market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

1. Introduction

1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 North America Lung Cancer Screening Market - by Technology
- 1.3.2 North America Lung Cancer Screening Market - by Cancer Type
- 1.3.3 North America Lung Cancer Screening Market - by Age Group
- 1.3.4 North America Lung Cancer Screening Market - by End User
- 1.3.5 North America Lung Cancer Screening Market - by Country

2. North America Lung Cancer Screening Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Lung Cancer Screening Market - Market Landscape

4.1 Overview
4.2 North America PEST Analysis
4.3 Expert's Opinion

5. North America Lung Cancer Screening Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Lung Cancer Incidences
- 5.1.2 Increasing Government Support
5.2 Market Restraints
- 5.2.1 High Cost of Lung Cancer Screening Tests
5.3 Market Opportunities
- 5.3.1 Structured Lung Cancer Screening Program
5.4 Future Trends
- 5.4.1 Use of Cutting-Edge Technologies
5.5 Impact Analysis

6. Lung Cancer Screening Market - North America Analysis

6.1 North America Lung Cancer Screening Market Revenue Forecast and Analysis

7. North America Lung Cancer Screening Market - Revenue and Forecast to 2028 - By Cancer Type

7.1 Overview
7.2 North America Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
7.3 Non-Small Cell Lung Cancer (NSCLC)
- 7.3.1 Overview
- 7.3.2 Non-Small Cell Lung Cancer (NSCLC): North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Mn)
7.4 Small Cell Lung Cancer
- 7.4.1 Overview
- 7.4.2 Small Cell Lung Cancer: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Lung Cancer Screening Market Analysis - by Technology

8.1 Overview
8.2 Low-Dose Computed Tomography (LDCT)
- 8.2.1 Overview
- 8.2.2 Low-Dose Computed Tomography (LDCT): North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
8.3 Chest X-ray
- 8.3.1 Overview
- 8.3.2 Chest X-ray: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
8.4 Liquid Biopsy
- 8.4.1 Overview
- 8.4.2 Liquid Biopsy: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)

9. North America Lung Cancer Screening Market Analysis - by Age Group

9.1 Overview
9.2 & Older
- 9.2.1 Overview
- 9.2.2 & Older: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Below 50
- 9.3.1 Overview
- 9.3.2 Below 50: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Lung Cancer Screening Market Analysis - by End User

10.1 Overview
10.2 Hospitals
- 10.2.1 Overview
- 10.2.2 Hospitals: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Diagnostic Centers
- 10.3.1 Overview
- 10.3.2 Diagnostic Centers: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
10.4 Others
- 10.4.1 Overview
- 10.4.2 Others: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)

11. North America Lung Cancer Screening Market - Revenue and Forecast to 2028 - Country Analysis

11.1 North America Lung Cancer Screening Market Overview

12. North America Lung Cancer Screening Market-Industry Landscape

12.1 Recent Growth Strategies
- 12.1.1 Overview

13. Company Profiles

13.1 Intelerad Medical Systems
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Nuance Communications Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 GE HealthCare
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Medtronic
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Canon Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Koninklijke Philips NV
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Siemens AG
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 CVS Health
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 bioAffinity Technologies, Inc.
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 LungLife AI, Inc.
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms

簡介目錄圖表

List Of Tables

List of Tables

Table 1. US North America Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 2. US North America Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 3. US North America Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 4. US North America Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 5. Canada North America Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 6. Canada North America Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 7. Canada North America Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 8. Canada North America Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 9. Mexico North America Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 10. Mexico North America Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 11. Mexico North America Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 12. Mexico North America Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 13. Recent Growth Strategies in the North America Lung Cancer Screening Market
Table 14. Glossary of Terms

List Of Figures

List of Figures

Figure 1. North America Lung Cancer Screening Market Segmentation
Figure 2. North America Lung Cancer Screening Market, by Country
Figure 3. North America Lung Cancer Screening Market Overview
Figure 4. Non-Small Cell Lung Cancer Segment Held Largest Share of Cancer Type Segment in North America Lung Cancer Screening Market
Figure 5. North America Expected to Show Remarkable Growth During Forecast Period
Figure 6. North America: PEST Analysis
Figure 7. Experts' Opinion
Figure 8. North America Lung Cancer Screening Market Impact Analysis of Driver and Restraints
Figure 9. North America Lung Cancer Screening Market - Revenue Forecast and Analysis - 2020-2030
Figure 10. North America Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
Figure 11. Non-Small Cell Lung Cancer (NSCLC): North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Small Cell Lung Cancer: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. North America Lung Cancer Screening Market, by Technology, 2022 & 2030 (%)
Figure 14. Low-Dose Computed Tomography (LDCT): North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 15. Chest X-ray: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 16. Liquid Biopsy: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America Lung Cancer Screening Market, by Age group, 2022 & 2030 (%)
Figure 19. & Older: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Below 50: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. North America Lung Cancer Screening Market, by End User, 2022 & 2030 (%)
Figure 22. Hospitals: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Diagnostic Centers: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. North America Lung Cancer Screening Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. North America Lung Cancer Screening Market Revenue Share, by Key Country, (2022 & 2030)
Figure 27. US: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. Canada: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. Mexico: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)